Controversy between Obesity and Complications in Thromboembolic Disease, Series of Cases of Fuenlabrada University Hospital in Tinzaparine Treatment

B Losada,D Gutierrez,Ja Guerra,P Bravo,I Juez,J Calzas

doi:10.21767/2575-7725.100010

Abstract

Thromboembolic disease is the second leading cause of death in cancer patients (mostly, in the first year from diagnosis). The needing for anticoagulation with low molecular weight heparin (LMWH) in patients who are at high risk for complications (risk of bleeding in digestive tumors, brain tumors ...) require us to be more aware of their evolution. In addition, presenting venous thromboembolic disease (VTE) is usually an exclusion criterion in clinical trials so we do not know what happens with the combination of new drugs. Our objective is to study in a sample of 31 patients diagnosed with VTE, whether incidence of complications such as re-thrombosis or bleeding is higher in patients treated with tinzaparin (LMWH) depending on BMI.

Highlights

Introduction and ObjectivesHospital University of Fuenlabrada, Calle Camino del Molino, 2, 28942 Fuenlabrada, Madrid, Spain
Venous thromboembolic disease (VTE) is present in up to 20% of oncology patients, presenting a lower recurrence in patients treated with low molecular weight heparin (LMWH) than with antivitamin K drugs (10-17% vs. 6-9%)
31 patients were treated with therapeutic doses of tinzaparin (LMWH) after diagnosis of pulmonary thromboembolism (PE), catheter thrombosis and/or deep venous thrombosis (DVT)

Summary

Introduction

Introduction and ObjectivesHospital University of Fuenlabrada, Calle Camino del Molino, 2, 28942 Fuenlabrada, Madrid, Spain. Venous thromboembolic disease (VTE) is present in up to 20% of oncology patients, presenting a lower recurrence in patients treated with low molecular weight heparin (LMWH) than with antivitamin K drugs (10-17% vs 6-9%). They offer doubts about the doses when the pharmacokinetic parameters are altered (as in the elderly, renal failure and obese) since the data in the literature are very scarce because they are excluded from the majority of clinical trials. It may be useful in these cases to monitor AntiXa activity [1,2]

Objectives

Results

Discussion

Conclusion